NASDAQ:ZURA • KYG9TY5A1016
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ZURA BIO LTD (ZURA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-23 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-09 | Wedbush | Initiate | Outperform |
| 2025-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-13 | Clear Street | Initiate | Buy |
| 2025-09-30 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-19 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-08-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-03 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-03-26 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-26 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-24 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-12-11 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-04 | Leerink Partners | Initiate | Outperform |
| 2024-10-21 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-18 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-09-19 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-09-05 | HC Wainwright & Co. | Initiate | Neutral |
| 2024-08-15 | Cantor Fitzgerald | Reiterate | Overweight |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A -75.00% | N/A 100.00% | N/A 1,473.57% | N/A 127.97% | N/A 79.11% | N/A -1.30% | ||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | -55.18M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -890K | -2.68M -201.12% | -62.638M -2,237.24% | -55.189M 11.89% | N/A -40.09% | N/A -6.10% | N/A 4.75% | N/A -57.84% | N/A -38.84% | N/A 33.45% | N/A 153.47% | N/A 398.57% | N/A -7.84% | ||
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -0.55 79.44% | N/A -39.36% | N/A -0.27% | N/A 14.15% | N/A -5.13% | N/A -88.24% | N/A -9.37% | N/A 82.14% | N/A | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 -100.43% | -0.22 -13.27% | -0.22 -31.00% | -0.22 -5.24% | -0.21 -6.02% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.657M -24.95% | -20.546M -6.71% | -21.662M -19.93% | -22.415M -14.83% | -22.937M -16.68% |
All data in USD
14 analysts have analysed ZURA and the average price target is 16.17 USD. This implies a price increase of 197.32% is expected in the next year compared to the current price of 5.44.
ZURA BIO LTD (ZURA) will report earnings on 2026-04-01, before the market open.
The consensus EPS estimate for the next earnings of ZURA BIO LTD (ZURA) is -0.2 USD and the consensus revenue estimate is 0 USD.